Yeah, in the rest of the session, we had wonderful talks on hormone receptor positive, HER2-negative disease, with the big advances being how do we best incorporate CDK4/6 inhibitors, and increasingly clear use in the first-line setting is appropriate, particularly with the overall survival advantage gene in the MONALEESA trials.
Also, the second-line and how do we use these drugs or other drugs in the later line setting and after CDK4/6 inhibitors with maintain and the appropriateness of potentially continuing them...
Yeah, in the rest of the session, we had wonderful talks on hormone receptor positive, HER2-negative disease, with the big advances being how do we best incorporate CDK4/6 inhibitors, and increasingly clear use in the first-line setting is appropriate, particularly with the overall survival advantage gene in the MONALEESA trials.
Also, the second-line and how do we use these drugs or other drugs in the later line setting and after CDK4/6 inhibitors with maintain and the appropriateness of potentially continuing them. Also, the use of ctDNA to kind of guide the tailored use, I think these are emerging arenas for research, but there’s actual clinical data coming out.
And the last is, how do you get past endocrine therapy? And we used to all have to go straight to free chemotherapy. The antibody drug conjugates are actually moving into that space also, quite successfully, with both trastuzumab deruxtecan and the DESTINY-04 trial showing a significant advantage, both PFS and overall survival. And the same for sacituzumab govitecan in the TROPiCS-02 study. So a lot to help us with all of the lines, because all of these patients are living longer now and having these drugs available so that we can keep them alive better and longer is the name of the game. We’re still not curing anyone, but I think we’ll get there.